SCHEMBL370810

SCHEMBL370810

C=CC(O)OC(=O)/C=C\C(=O)OC(O)C=C

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 3/20 0.39
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370883 1.00 HCAR2 (0.39) HCAR2KEAP1NFE2L2
SCHEMBL2705194 1.00 HCAR2 (0.39) HCAR2KEAP1NFE2L2
SCHEMBL370812 0.91 HCAR2 (0.54) HCAR2
SCHEMBL370811 0.91 HCAR2 (0.54) HCAR2
SCHEMBL370884 0.91 HCAR2 (0.54) HCAR2
SCHEMBL656054 0.86 HCAR2 (0.34) HCAR2
SCHEMBL656053 0.86 HCAR2 (0.34) HCAR2
SCHEMBL8019533 0.86 HCAR2 (0.30) HCAR2
SCHEMBL8773230 0.84
SCHEMBL29155 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240000710-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS NITTO DENKO CORPORATION (JP) 2024-01-04 US claimed
EP-3324932-B1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS NITTO DENKO CORP (JP) 2021-03-10 EP claimed
US-20190231695-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS NITTO DENKO CORPORATION (JP) 2019-08-01 US claimed
US-10300018-B2 Compositions and methods for nanoparticle lyophile forms NITTO DENKO CORPORATION (JP) 2019-05-28 US claimed
EP-3324932-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS Nitto Denko Corporation (JP) 2018-05-30 EP claimed
US-20170020819-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS NITTO DENKO CORPORATION (JP) 2017-01-26 US claimed
WO-2017015552-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS NITTO DENKO CORPORATION (JP) 2017-01-26 WO claimed
US-6783006-B1 Container for chemicals SYNGENTA INVESTMENT CORP. 2004-08-31 US claimed
EP-0746514-B1 PROCESS FOR THE FABRICATION OF A CONTAINER FOR CHEMICALS NOVARTIS AG (CH) 1999-04-14 EP claimed
EP-0746514-A1 CONTAINER FOR CHEMICALS Novartis AG (CH) 1996-12-11 EP claimed
EP-0739297-A1 A PACKAGE SYSTEM FOR CHEMICALS Novartis AG (CH) 1996-10-30 EP claimed
WO-1995023099-A1 CONTAINER FOR CHEMICALS CIBA-GEIGY AG (CH) 1995-08-31 WO claimed
WO-1995019921-A1 A PACKAGE SYSTEM FOR CHEMICALS CIBA-GEIGY AG (CH) 1995-07-27 WO claimed
EP-0046136-B1 MEMBRANE MODIFIED HYDROGELS, PROCESS FOR THEIR MANUFACTURE AND THEIR USE AS ACTIVE AGENT DISPENSER CIBA-GEIGY AG (CH) 1984-05-30 EP claimed
EP-0046136-A2 Membrane modified hydrogels, process for their manufacture and their use as active agent dispenser CIBA-GEIGY AG (CH) 1982-02-17 EP claimed
US-4304591-A A HIGH-STRENGTH GEL OF MALEIMIDE-MODIFIED POLYOXYPROPYLENE OR -TETRAMETHYLENE GLYCOL CROSSLINKED BY A WATER-SOLUBLE OLEFIN; SUSTAINED RELEASE CIBA-GEIGY CORPORATION (US) 1981-12-08 US claimed
US-4277582-A MEMBRANES AND CARRIERS FOR SUSTAINED RELEASE CIBA-GEIGY CORPORATION (US) 1981-07-07 US claimed
US-4192827-A IN A DELAMINATED MATRIX OF A TRANSITITION METAL DICHALCOGENIDE CIBA-GEIGY CORPORATION (US) 1980-03-11 US claimed
US-4177056-A CROSSLINKED; SUSTAINED RELEASE CIBA-GEIGY CORPORATION (US) 1979-12-04 US claimed
US-4136250-A CROSSLINKED, ADDITION MONOMER OR POLYMER CIBA-GEIGY CORPORATION (US) 1979-01-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240000710-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS DDOST, RNASE1, DIS3 HCAR2 4816/4885KEAP1 2586/4885NFE2L2 4715/4885
US-20190231695-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS DDOST, RNASE1, DIS3 HCAR2 4817/4885KEAP1 2174/4885NFE2L2 4752/4885
US-20170020819-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS DDOST, RNASE1, DIS3 HCAR2 4817/4885KEAP1 2174/4885NFE2L2 4752/4885
US-10300018-B2 Compositions and methods for nanoparticle lyophile forms DDOST, RNASE1, DIS3 HCAR2 4817/4885KEAP1 2174/4885NFE2L2 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.